# Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

> **NCT01967576** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Pheochromocytoma
- Paraganglioma

## Interventions

- **DRUG:** Axitinib (AG-013736)

## Key facts

- **NCT ID:** NCT01967576
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-19
- **Primary completion:** 2015-06-29
- **Final completion:** 2020-12-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01967576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01967576, "Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01967576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*